These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17452962)

  • 1. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
    Edelman SV; Garg S; Kolterman OG
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):E1; discussion E2. PubMed ID: 17452962
    [No Abstract]   [Full Text] [Related]  

  • 2. Is pramlintide an adjunct to insulin therapy?
    Charles MA
    Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
    [No Abstract]   [Full Text] [Related]  

  • 3. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.
    Elkind-Hirsch K; Butler WJ; Bhushan M; Hirsch D; Bhushan R
    Diabetes Care; 2008 Jan; 31(1):39-40. PubMed ID: 17909093
    [No Abstract]   [Full Text] [Related]  

  • 6. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
    Pullman J; Darsow T; Frias JP
    Vasc Health Risk Manag; 2006; 2(3):203-12. PubMed ID: 17326327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
    Ratner R; Whitehouse F; Fineman MS; Strobel S; Shen L; Maggs DG; Kolterman OG; Weyer C
    Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):199-204. PubMed ID: 15891954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunct therapy for type 1 diabetes mellitus.
    Lebovitz HE
    Nat Rev Endocrinol; 2010 Jun; 6(6):326-34. PubMed ID: 20404854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
    Marrero DG; Crean J; Zhang B; Kellmeyer T; Gloster M; Herrmann K; Rubin R; Fineberg N; Kolterman O
    Diabetes Care; 2007 Feb; 30(2):210-6. PubMed ID: 17259483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.
    Rubin RR; Peyrot M
    Curr Med Res Opin; 2007 Aug; 23(8):1919-29. PubMed ID: 17624233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.
    Kishiyama CM; Burdick PL; Cobry EC; Gage VL; Messer LH; McFann K; Chase HP
    Pediatrics; 2009 Nov; 124(5):1344-7. PubMed ID: 19858155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amylin's pramlintide best of bad bunch of diabetes drugs.
    Brower V
    Nat Biotechnol; 1997 Oct; 15(10):935. PubMed ID: 9335036
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic management of type 1 diabetes: a review for dentistry.
    Little JW; Rhodus NL
    Gen Dent; 2007; 55(5):403-9. PubMed ID: 17899716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.
    Nogid A; Pham DQ
    Pharmacotherapy; 2006 Nov; 26(11):1626-40. PubMed ID: 17064208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
    Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
    Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide acetate.
    McQueen J
    Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.